Vanda Pharmaceuticals

Update in progress

VNDA (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Vanda Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs worldwide. Its portfolio includes Fanapt for bipolar I disorder and schizophrenia; HETLIOZ for non-24-hour sleep-wake disorders; PONVORY for relapsing forms of multiple sclerosis; and NEREUSTM to prevent motion sickness. It also pursues long-acting formulations, CNS and immunology programs, and CFTR/antisense research. Founded in 2002, based in Washington, DC.

Company score

Sentiment: 0.60; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.29; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.36; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGM (NGM)
LocationUnited States
CEODr. Mihael H. Polymeropoulos M.D.
Founded2002
Employees533
Websitewww.vandapharma.com

Identifiers

ISINUS9216591084
FIGIBBG000HT5MG6
LEI529900AY8VOOQBKJ0O70
CUSIP921659108
CIK0001347178